107 related articles for article (PubMed ID: 25897103)
41. Efficiency of diagnostic biomarkers among colonic schistosomiasis Egyptian patients.
Hamed MA; Ahmed SA; Khaled HM
Mem Inst Oswaldo Cruz; 2011 May; 106(3):322-9. PubMed ID: 21655820
[TBL] [Abstract][Full Text] [Related]
42. The Diagnostic and Prognostic Significance of Serum Neutrophil Gelatinase-Associated Lipocalin Levels in Patients with Colorectal Cancer.
Ozemir IA; Aslan S; Eren T; Bayraktar B; Bilgic C; Isbilen B; Yalman H; Yigitbasi R; Alimoglu O;
Chirurgia (Bucur); 2016; 111(5):414-421. PubMed ID: 27819647
[TBL] [Abstract][Full Text] [Related]
43. Detection and evaluation of epithelial cells in the blood of colon cancer patients using RT-PCR.
Katsumata K; Sumi T; Mori Y; Hisada M; Tsuchida A; Aoki T
Int J Clin Oncol; 2006 Oct; 11(5):385-9. PubMed ID: 17058136
[TBL] [Abstract][Full Text] [Related]
44. Prognostic value of circulating cytokines in colon cancer recurrence.
Kilzi GM; Lavu H
J Surg Res; 2014 Jan; 186(1):85-6. PubMed ID: 23465432
[No Abstract] [Full Text] [Related]
45. Oncostatin-M as a novel biomarker in colon cancer patients and its association with clinicopathologic variables.
Gurluler E; Tumay LV; Guner OS; Kucukmetin NT; Hizli B; Zorluoglu A
Eur Rev Med Pharmacol Sci; 2014; 18(14):2042-7. PubMed ID: 25027345
[TBL] [Abstract][Full Text] [Related]
46. Upregulated miR-16 expression is an independent indicator of relapse and poor overall survival of colorectal adenocarcinoma patients.
Diamantopoulos MA; Kontos CK; Kerimis D; Papadopoulos IN; Scorilas A
Clin Chem Lab Med; 2017 May; 55(5):737-747. PubMed ID: 27930363
[TBL] [Abstract][Full Text] [Related]
47. Comparison of colorectal neoplastic polyps and adenocarcinoma with regard to NLR and PLR.
Emir S; Aydin M; Can G; Bali I; Yildirim O; Öznur M; Yildiz ZD; Sözen S; Gürel A
Eur Rev Med Pharmacol Sci; 2015 Oct; 19(19):3613-8. PubMed ID: 26502851
[TBL] [Abstract][Full Text] [Related]
48. Serum levels of ADAM10, ADAM12, ADAM17 AND ADAM28 in colorectal cancer patients.
Walkiewicz K; Nowakowska-Zajdel E; Strzelczyk J; Dzięgielewska-Gęsiak S; Muc-Wierzgoń M
J Biol Regul Homeost Agents; 2017; 31(4):929-934. PubMed ID: 29254295
[TBL] [Abstract][Full Text] [Related]
49. Clinical value of a diagnostic score for colon cancer based on serum CEA, CA19-9, cytokeratin-1 and mucin-1.
Attallah AM; El-Far M; Ibrahim AR; El-Desouky MA; Omran MM; Elbendary MS; Attallah KA; Qura ER; Abdallah SO
Br J Biomed Sci; 2018 Jul; 75(3):122-127. PubMed ID: 29734875
[TBL] [Abstract][Full Text] [Related]
50. Cholesterolemia in colorectal cancer.
Forones NM; Falcao JB; Mattos D; Barone B
Hepatogastroenterology; 1998; 45(23):1531-4. PubMed ID: 9840100
[TBL] [Abstract][Full Text] [Related]
51. [Predictive value of combination detection of tissue Pgp1 expression and preoperative serum CEA level for colorectal cancer].
Wu F; Chen L; Wu W; Jiang B; Su X
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Apr; 20(4):443-449. PubMed ID: 28440527
[TBL] [Abstract][Full Text] [Related]
52. beta-N-acetylglucosaminidase and beta-glucuronidase activities in insulin-dependent diabetic subjects with retinopathy.
Pitkänen E; Kyllästinen M; Koivula T; Hormila P
Diabetologia; 1980 Apr; 18(4):275-8. PubMed ID: 7418953
[TBL] [Abstract][Full Text] [Related]
53. Enzymes in colon cancer. General information.
Schwartz MK
Cancer; 1975 Dec; 36(6 Suppl):2334-6. PubMed ID: 764957
[TBL] [Abstract][Full Text] [Related]
54. Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.
Akbulut H; Altuntas F; Akbulut KG; Ozturk G; Cindoruk M; Unal E; Icli F
Cytokine; 2002 Nov; 20(4):184-90. PubMed ID: 12543084
[TBL] [Abstract][Full Text] [Related]
55. Prolactin and colorectal cancer: is there a connection?
Baert D; Matthys C; Gillardin JP; Lepoutre L; Thienpont L; Kaufman JM; Cuvelier C; De Vos M
Acta Gastroenterol Belg; 1998; 61(4):407-9. PubMed ID: 9923090
[TBL] [Abstract][Full Text] [Related]
56. Heparanase expression correlates with malignant potential in human colon cancer.
Nobuhisa T; Naomoto Y; Ohkawa T; Takaoka M; Ono R; Murata T; Gunduz M; Shirakawa Y; Yamatsuji T; Haisa M; Matsuoka J; Tsujigiwa H; Nagatsuka H; Nakajima M; Tanaka N
J Cancer Res Clin Oncol; 2005 Apr; 131(4):229-37. PubMed ID: 15625607
[TBL] [Abstract][Full Text] [Related]
57. Selective decrease of serum immunoglobulin G1 as a marker of malignant transformation in colorectal tissue.
Schauenstein E; Rabl H; Steinschifter W; Hirschmann C; Estelberger W; Schauenstein K
Cancer; 1997 Apr; 79(8):1482-6. PubMed ID: 9118027
[TBL] [Abstract][Full Text] [Related]
58. Tenascin-W, a new marker of cancer stroma, is elevated in sera of colon and breast cancer patients.
Degen M; Brellier F; Schenk S; Driscoll R; Zaman K; Stupp R; Tornillo L; Terracciano L; Chiquet-Ehrismann R; Rüegg C; Seelentag W
Int J Cancer; 2008 Jun; 122(11):2454-61. PubMed ID: 18306355
[TBL] [Abstract][Full Text] [Related]
59. Combination of serum lipids and cancer antigens as a novel marker for colon cancer diagnosis.
Li T; Qian Y; Li H; Deng J
Lipids Health Dis; 2018 Nov; 17(1):261. PubMed ID: 30458796
[TBL] [Abstract][Full Text] [Related]
60. Comparison of mouse and human colon tumors with regard to phase I and phase II drug-metabolizing enzyme systems.
Massaad L; de Waziers I; Ribrag V; Janot F; Beaune PH; Morizet J; Gouyette A; Chabot GG
Cancer Res; 1992 Dec; 52(23):6567-75. PubMed ID: 1423302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
